2898 — Sunho Biologics Income Statement
0.000.00%
Last trade - 00:00HealthcareMid Cap
- HK$10.55bn
- HK$10.53bn
- CNY56.13m
Annual income statement for Sunho Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 46.9 | 132 | 79 |
| Operating Profit | -46.9 | -132 | -79 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -52 | -133 | -80 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -52 | -133 | -80 |
| Net Income Before Extraordinary Items | |||
| Net Income | -52 | -133 | -80 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -52 | -133 | -80 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.403 | -0.722 | -0.422 |